Setback in Indian Court Compounds Challenges for Novo Nordisk

Novo Nordisk faces mounting headwinds as a recent legal decision in India deals a blow to its patent strategy. A Delhi court has denied the Danish pharmaceutical giant’s request for an interim injunction against competitor Dr. Reddy’s Laboratories, permitting the continued export of semaglutid. This ruling weakens Novo Nordisk’s patent protection in key markets, arriving during a period of significant pressure on the company’s share price.

Legal Decision Paves Way for Competitive Exports

The court’s refusal to block Dr. Reddy’s allows the Indian firm to keep manufacturing and exporting semaglutid—the active ingredient in blockbuster drugs Ozempic and Wegovy—to nations where Novo Nordisk does not hold enforceable patents. While Dr. Reddy’s is barred from selling the drug within India itself until March 2026, when the local patent expires, the export permission is a substantial setback.

Key developments from the ruling:

• Production of semaglutid for export by Dr. Reddy’s can continue.
• The Indian domestic market remains protected for Novo Nordisk until patent expiry in March 2026.
• In response, Novo Nordisk has accelerated plans to launch Ozempic in India this December.

The strategic move to introduce its brand in the world’s most populous country ahead of the 2026 patent cliff is clear. However, the authorized exports from India could intensify pricing pressure in other regions much sooner. Concurrently, regulatory scrutiny is rising in South Korea, where concerns over the misuse of Wegovy for cosmetic weight loss and illegal prescriptions to minors may lead to stricter dispensing rules, potentially dampening sales growth in Asian markets.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

A Challenging Year Intensifies

This patent defeat comes at an inopportune moment for Novo Nordisk. The company’s stock has declined by approximately 50% in 2025. Just days before the Indian court’s decision, on December 4, the company faced another disappointment: phase 3 trials for oral semaglutid in Alzheimer’s disease failed to meet their primary endpoint. Investor hopes for expansion into neurodegenerative treatments were dashed, triggering a sharp sell-off.

A sliver of positive news emerged from Germany this week, where the Federal Cartel Office approved Novo Nordisk’s acquisition of Akero Therapeutics. This deal is intended to diversify the company’s pipeline beyond GLP-1 agonists, particularly into treatments for liver-related metabolic diseases.

Nevertheless, these developments are currently insufficient to counterbalance the negative sentiment. The prevailing technical downtrend for the shares remains unbroken. The critical question for investors is whether the upcoming India launch and a robust response to mounting competition from Eli Lilly can catalyze a reversal. Alternatively, further legal defeats and clinical trial disappointments may continue to weigh on the valuation through year-end.